Jazz Pharmaceuticals plc – (JAZZ) Rating Lowered to Neutral at Mizuho

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was downgraded by Mizuho from a “buy” rating to a “neutral” rating in a note issued to investors on Thursday. They currently have a $150.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $162.00. Mizuho’s price objective indicates a potential downside of 1.86% from the company’s current price.

Several other equities analysts have also issued reports on the stock. BMO Capital Markets reaffirmed a “top pick” rating and issued a $192.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, February 15th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Vetr lowered shares of Jazz Pharmaceuticals plc – from a “strong-buy” rating to a “buy” rating and set a $161.19 price target on the stock. in a report on Monday, March 27th. Goldman Sachs Group Inc reaffirmed a “buy” rating and issued a $170.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, January 18th. Finally, Cantor Fitzgerald initiated coverage on shares of Jazz Pharmaceuticals plc – in a report on Friday, December 16th. They issued an “overweight” rating and a $187.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $181.23.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.89% on Thursday, hitting $152.84. The company’s stock had a trading volume of 436,725 shares. Jazz Pharmaceuticals plc – has a 12 month low of $95.80 and a 12 month high of $160.00. The firm has a 50 day moving average of $143.48 and a 200 day moving average of $123.54. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of 23.84 and a beta of 1.22.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.65 by $0.74. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The business had revenue of $396.62 million for the quarter, compared to analysts’ expectations of $398.91 million. During the same period in the previous year, the business earned $2.60 earnings per share. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals plc – will post $11.10 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Jazz Pharmaceuticals plc – (JAZZ) Rating Lowered to Neutral at Mizuho” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.themarketsdaily.com/2017/04/21/jazz-pharmaceuticals-plc-jazz-lowered-to-neutral-at-mizuho-updated.html.

In related news, SVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $152.56, for a total transaction of $30,512.00. Following the completion of the transaction, the senior vice president now directly owns 22,562 shares in the company, valued at $3,442,058.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Tuesday, April 11th. The shares were sold at an average price of $152.12, for a total transaction of $152,120.00. Following the transaction, the chief executive officer now owns 308,491 shares of the company’s stock, valued at $46,927,650.92. The disclosure for this sale can be found here. Insiders have sold 13,942 shares of company stock valued at $2,098,147 over the last 90 days. 3.90% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Howard Hughes Medical Institute purchased a new position in shares of Jazz Pharmaceuticals plc – during the third quarter worth $112,000. Brave Asset Management Inc increased its position in shares of Jazz Pharmaceuticals plc – by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 810 shares during the period. Daiwa Securities Group Inc. increased its position in shares of Jazz Pharmaceuticals plc – by 10.7% in the third quarter. Daiwa Securities Group Inc. now owns 1,550 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 150 shares during the period. Mn Services Vermogensbeheer B.V. increased its position in shares of Jazz Pharmaceuticals plc – by 2.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,557 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 37 shares during the period. Finally, Bridges Investment Management Inc. purchased a new position in shares of Jazz Pharmaceuticals plc – during the first quarter worth $208,000. Institutional investors and hedge funds own 88.56% of the company’s stock.

Jazz Pharmaceuticals plc – Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply